Background: Nociceptin in the peripheral circulation has been proposed to have an immunoregulatory role with regards to inflammation and pain. However, the mechanisms involved in its regulation are still not clear. The aim of this study was to investigate signalling pathways contributing to the regulation of the expression of nociceptin under inflammatory conditions. Methods: Mono Mac 6 cells (MM6) were cultured with or without phorbol-12-myristate-13-acetate (PMA). Prepronociceptin (ppNOC) mRNA was detected by RT-qPCR and extracellular nociceptin by fluorescent-enzyme immunoassay. Intracellular nociceptin and phosphorylated kinases were measured using flow cytometry. To evaluate the contribution of various signalling pathways to the regulation of ppNOC mRNA and nociceptin protein, cells were pre-treated with specific kinase inhibitors before co-culturing with PMA. Results: ppNOC mRNA was expressed in untreated MM6 at low concentrations. Exposure of cells to PMA upregulated ppNOC after nine h compared with controls without PMA (median normalized ratio with IQR: 0.18 (0.15-0.26) vs. 0 (0-0.02), P<0.01). Inhibition of mitogen-activated protein kinases specific for signal transduction reversed the PMA effects (all P<0.001). Induction of nociceptin protein concentrations in PMA stimulated MM6 was prevented predominantly by identity of ERK inhibitor (P<0.05). Conclusions: Upregulation of nociceptin expression by PMA in MM6 cells involves several pathways. Underlying mechanisms involved in nociceptin expression may lead to new insights in the treatment of pain and inflammatory diseases.
(PMA), a potent inflammatory mediator, activates monocytic cells by a protein kinase C with dependent mechanism.
14 It is well established that PMA induces its effects via activation of multiple signalling pathways including three MAPKs, extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK) and p38, and the NFκB pathway. 15 16 The aim of the present study was to investigate the regulation of nociceptin in MM6 by PMA and to explore possible signal transduction mechanisms contributing to the expression of nociceptin, in MM6 under inflammatory conditions.
Methods

Cell cultures
MM6 were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U ml −1 penicillin, 100 µg ml −1 streptomycin, 10 μg ml −1 insulin, 1 mM sodium pyruvate and 1× non-essential amino acids (all from Sigma-Aldrich, Buchs, Switzerland) at 37°C and 5% CO 2 atmosphere. Cells were seeded at a density of 1.5×10 5 cells ml −1 in flat-bottomed 24-well plates (BD Bioscience, Allschwil, Switzerland).
Cell viability assay
Cells were co-cultured with different concentrations of PMA (0.01-100 ng ml −1 ) (Sigma-Aldrich, Buchs, Switzerland) or without any treatment for up to 48 h. Cell viability was analysed by flow cytometry (BD LSR II, Allschwil, Switzerland) using annexin V/propidium iodide double staining according to the manufacturer's instructions (eBioscience, Vienna, Austria). Viable cell count was presented as a percentage of the respective untreated samples.
Stimulation of cells with PMA
To investigate the influence of PMA on ppNOC mRNA expression in MM6, cells were treated with different concentrations of PMA (0.01-100 ng ml −1 ) or without PMA for 24 h. According to these pilot experiments, 1 and 10 ng ml −1 PMA were used in subsequent cultures.
Interference with signal transduction pathways
Further experiments using specific kinase inhibitors were conducted to test the contribution of signalling pathways to nociceptin expression in MM6. Cells were pre-treated with PD98059 (PD) 30 µM, SP600125 (SP) 10 µM, SB203580 (SB) 10 µM or Bay 11-7821 (Bay) 3 µM (all from Tocris bioscience, Bristol, UK) for one h before co-culturing with 1 or 10 ng ml −1 PMA for 24 h. The concentrations of the inhibitors were chosen according to previous studies. 17 18 In addition, a control group without any stimuli and reference groups co-cultured with respective kinase inhibitors or PMA only were included. After the culture, cells were collected for RNA isolation or for intracellular phosphorylated kinases and nociceptin detection. Supernatants of the cultures were used for measurement of nociceptin protein concentrations.
RNA isolation, cDNA synthesis and relative quantification
At each predefined time point, cells were collected and total RNA was isolated (QIAamp® RNA Blood Mini kit; Qiagen, Hombrechtikon, Switzerland). RNA concentrations and purity were measured using a NanoDrop 2000 (Thermo Scientific, Reinach, Switzerland Primer sequences were as follows: HPRT1, 5′-TGACCTTGATT TATTTTGCATACC-3′ and 5′-CGAGCAAGACGTTCAGTCCT-3′; POLR2A, 5′-GCAAATTCACCAAGAGAGACG-3′ and 5′-CACGTCGA CAGGAACATCAG-3′; ppNOC, 5′-GGACAGCTTCGACCTGGAG-3′ and 5′-TGACCTTGGTGCATGGAGT-3′. PCR conditions were the following: 95°C for 10 min, 45 cycles of 95°C for 10 s, 60°C for 30 s and signal detection at 72°C for one s followed by cooling at 40°C for 30 s. Standard curves were generated by amplification of ppNOC, HPRT1 and POLR2A in a series of diluted cDNA in triplicate. The Advanced Relative Quantification module of the LightCycler ® 480 Software (Roche, Rotkreuz, Switzerland) was used to quantify ppNOC mRNA concentrations based on the qPCR efficiencies and the crossing point difference and expressed as the ratio of ppNOC/HPRT1 and POLR2A of each sample normalized to the calibrator used in the PCR reactions. 19 
Flow cytometry
Measurement of intracellular nociceptin After co-incubation with or without PMA 1 or 10 ng ml −1 PMA for 24 h, cells were collected, fixed and permeabilized for 20 min on ice by adding Cytofix/Cytoperm solution 500 µl per 1×10 6 cells (BD Biosciences, Allschwil, Switzerland). Cells were subsequently pelleted and re-suspended and after centrifugation, Fc receptors were blocked by incubation with 10% human serum type AB (Sigma-Aldrich, Buchs, Switzerland), then for 10 min at room temperature (RT). Cells were subsequently stained with anti-nociceptin antibody (Phoenix Pharmaceuticals, Karlsruhe, Germany) or isotype-control antibody (R&D Systems, Oxford, UK) for one h at RT. Samples were then washed and stained with FITC-conjugated secondary antibody (BD Biosciences, Allschwil, Switzerland) for one h at RT in the dark, washed and analysed using flow cytometry. Cells without PMA co-incubation served as controls.
Editor's key points
• Nociceptin released from peripheral leucocytes may have a role in inflammation.
• The precise signalling pathways involved are not known.
• Cells from a human monocyte macrophage cell line were exposed to phorbol myristate acetate (PMA) to mimic inflammation.
• Expression of intracellular nociceptin and various kinases were determined with and without inhibitors.
• Upregulation of nociceptin by PMA in macrophage involves several signalling pathways and may suggest targets for further study.
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Detection of phosphorylated kinases MM6 were pre-treated with different kinase inhibitors for one h before co-culturing with and without 10 ng ml −1 PMA for 15 min ( phosphorylated ERK ( pERK), pJNK and pp38) or one h ( pNFκB), then intracellular staining of specific phosphorylated kinases was performed as previously described. 20 Briefly, after the required time, cellular signalling was halted using 1.5% paraformaldehyde (AppliChem, Darmstadt, Germany). Fixed cells were centrifuged and permeabilized in ice cold methanol (AppliChem, Darmstadt, Germany) then incubated for 20 min on ice. Subsequently, cells were washed with staining buffer and Fc receptors on the cells were blocked by incubation with 10% human serum type AB for 10 min at RT. Samples were then stained with respective monoclonal antibodies specific to the phosphorylated form of intracellular kinases (all from BD Biosciences, Allschwil, Switzerland) for one h at RT in the dark, washed and analysed by flow cytometry.
Ten thousand cells of each gated population were analysed per sample and mean fluorescence intensity (MFI) which represents the expression quantity of the target proteins, was calculated using FlowJo V10 software (TreeStar Inc., Ashland, USA).
Fluorescent-enzyme immunoassay (F-EIA)
Measurement of nociceptin in supernatants Nociceptin protein concentrations in culture supernatants were measured using the nociceptin/orphanin FQ-fluorescent EIA kit according to manufacturer's protocol (Phoenix Pharmaceuticals, Karlsruhe, Germany). At each culture time point, samples were collected in chilled tubes containing aprotinin (600 KIU ml −1 ) and centrifuged and supernatants were acidified with an equal amount of buffer A, mixed, centrifuged and loaded onto a pretreated C-18 SEP-COLUMN. After washing with buffer A, peptides were eluted with buffer B (all from Phoenix Pharmaceuticals, Karlsruhe, Germany) and concentrated by a vacuum speed concentrator 5301 (Eppendorf, Hamburg, Germany). The pellet was reconstituted with assay buffer and loaded to the F-EIA plate in duplicate. A standard curve was generated for each plate. Fluorescence was detected by a Tecan 200 (Tecan, Grödig, Austria). The minimum detection level was 15.9 pg ml −1 and samples were concentrated seven-fold. Nociceptin concentrations in supernatants of samples without PMA served as a control.
Statistical analysis
Data are presented as medians with interquartile ranges (IQR) or as box and whisker plots showing median, interquartile and 5-95 percentiles. Statistical analysis was performed using STATISTICA 10.0 (StatSoft, Inc., Tulsa, OK, USA) and Mann-Whitney U-tests and Wilcoxon signed-rank tests were performed as appropriate with P<0.05 being considered statistically significant.
Results
Cell viability of MM6 cells exposed to PMA ≤1 ng ml −1 for up to 48 h exceeded 90% and although treatment with 10 or 100 ng ml −1 PMA did not influence MM6 cell viability up to 24 h, viability was 75.8 and 68.1% respectively after 48 h. Expression of ppNOC mRNA was barely detectable in untreated MM6 (median normalized ratio with IQR: 0 (0-0.01)). In cells treated with PMA, ppNOC mRNA expression was dose-dependently upregulated after 24 h with an ED 50 of 1.26 (95% confidence interval: 1.07-2.55) ng ml −1 (Fig. 1) . Expression was increased in a time-dependent manner after to PMA exposure at 1 or 10 ng ml
, for up to 48 h (Fig. 2) . Compared with controls without PMA, ppNOC mRNA concentrations were upregulated by 1 ng ml −1 PMA after 12 h and by 10 ng ml −1 PMA after nine h (both P<0.01). Maximum ppNOC mRNA expression was seen in cells treated with 10 ng ml −1 PMA for 24 h (Fig. 2) .
There was no change in intracellular nociceptin protein concentrations in MM6 cells treated with 1 ng ml −1 PMA compared with those without PMA (Fig. 3) . In contrast, nociceptin concentration was higher in cells treated with 10 ng ml −1 PMA (P<0.01, Fig. 3 and 3B) . Low fluorescent signals were seen in cells (with or without PMA) stained with isotype-control antibody compared with those stained with anti-nociceptin antibody (Fig. 3) . Elevated nociceptin protein concentrations were detected in supernatants of cells treated with 10 ng ml −1 PMA after 24 h compared with without PMA (P<0.05). Phospho-flow cytometry using specific phospho-protein antibodies revealed increased protein concentrations of pERK, pJNK, Medians and interquartile range, n=10. ***P<0.001.
pp38 and pNFκB in MM6 cells after treatment with 10 ng ml
PMA compared with without PMA (all P<0.01, Fig. 4 ). PMA-induced phosphorylation of ERK, JNK, p38 and NFκB was prevented when the cells were pre-treated with specific kinase inhibitors before PMA treatment (all P<0.05, Fig. 4) . To further verify possible signalling pathways contributing to nociceptin expression induced by PMA, cells were pre-treated with specific kinase inhibitors (PD, SP, SB and Bay). Pre-treatment of cells with PD, SP or SB completely prevented PMA induced upregulation of ppNOC mRNA compared with samples treated solely with PMA (all P<0.001, Fig. 5 ). In contrast, elevated ppNOC expression in 1 ng ml −1 PMA treated samples were only blocked by PD or SP compared with the cells treated with 1 ng ml −1 PMA only (both P<0.01). Pre-treatment of the cells with Bay 11-7821 did not affect upregulation of ppNOC mRNA expression induced by either concentration of PMA. Kinase inhibitors alone had no effects on ppNOC mRNA expression (Fig. 5 ).
Nociceptin protein upregulation by PMA was only prevented by pre-treatment with the ERK inhibitor PD98059 (P<0.05 , Fig. 6 ); the other inhibitors had no effect.
Discussion
The present results demonstrate that prepronociceptin ( ppNOC) mRNA and nociceptin protein are upregulated by PMA in MM6 cells. These findings are in line with previous studies using neuronal cells: nociceptin precursor mRNA was induced by inflammatory mediators in mouse NS20Y neuroblastoma cells and in rat primary-neuronal and astrocyte cultures. 21 22 In clinical settings, elevated plasma nociceptin or ppNOC mRNA have been reported in patients suffering from inflammatory diseases, cancer or pain. p38, and the NFκB pathway. 15 16 In addition, involvement of MAPKs and NFκB pathways in the regulation of prepronociceptin mRNA has been previously reported. 6 12 The current phospho-flow assay indicated that ERK, JNK, p38, and NFκB pathways were activated by PMA in MM6. Furthermore, a causal relationship between the activation of these signalling pathways and nociceptin expression was shown by blocking respective signalling pathways, using specific kinase inhibitors. Taken together, PMA-activated ERK, JNK, and p38 MAPKs seem to represent key signalling pathways controlling the upregulation of ppNOC mRNA in MM6. This is in contrast to oxidative stress and lipopolysaccharide induced proorphanin FQ and nociceptin/orphanin mRNA in rat-astrocyte cultures via MAPK-ERK, p38, and NFκB pathways, 6 12 There was no influence of NFκB on either ppNOC nor nociceptin protein in the present study. However, it should be pointed out that species differences, tissue or cell specificity, and the different inflammatory stimuli that were used in these diverse experiments may account for the differences. In the present study, both 1 and 10 ng ml −1 PMA upregulated ppNOC mRNA expression in MM6 after 24 h, whereas the suppressive effects of the p38 pathway inhibitor on the upregulation of ppNOC mRNA were only observed in cells co-cultured with 10 ng ml −1 PMA. Thus, it is likely that p38 is not a central signalling pathway involved in the upregulation of ppNOC mRNA in MM6 treated with low concentrations of PMA. It has been demonstrated that the impact of signalling pathways on gene expression depends on the level of activated components involved and the complexity of the cross-talk between them. 24 Moreover, cell response to a particular stimulus is not the result of a single linear signal, but rather reflects pathway integration, which can occur at multiple levels, exhibiting extensive cross-talk and forming networks of several receptors, resulting in positive or negative signal modulation. 25 26 Signalling cascades activated by extracellular stimuli trigger changes in gene expression including early and late response genes. Early response genes can be expressed within minutes of activation and may exert effects on expression of late response genes. 27 In the present study, ppNOC mRNA was upregulated by PMA after nine h, indicating that the nociceptin gene is a late response gene in the current experimental set-up. However, the molecular basis by which the MAPK signalling pathways reprogramme MM6 to elevated expression of nociceptin remains to be further elucidated. Additional modulating factors such as, for example, inflammatory cytokines 3 6 or the transcription factor Sp1 28 possibly contribute as well. In the current model, the upregulation of nociceptin was most pronounced at the mRNA level. One possible explanation might be the pharmacokinetic profile of nociceptin 29 and the fact that multiple post-transcriptional mechanisms participate in the processes of translating mRNA to protein. 30 The influence of cell density on the total production of extracellular nociceptin also needs to be considered. In a previous study, preformed nociceptin was detected in human neutrophils and instant secretion of this peptide was observed after cell stimulation. 31 The basal intracellular nociceptin protein detected in untreated MM6 cells, may indicate that nociceptin is weakly expressed and potentially processed rapidly in resting MM6. On the other hand, these basal concentrations of nociceptin might be a possible reason for the weak difference in intracellular nociceptin signals between the PMA-treated cells and the control groups. Nevertheless, the upregulated nociceptin protein detected in the current PMA-treated MM6, along with the previous findings that nociceptin receptor (NOP) is present in all subtypes of human blood leucocytes, 32 33 support the hypothesis that this neuropeptide plays a role in immune response in human peripheral blood, under inflammatory conditions. Fluorescent-EIA and flow cytometry were used for protein measurement, enabling increased sensitivity compared with the traditional enzyme immunoassay; flow cytometry notably allows quantification of proteins at a single cell level. 34 Nociceptin has been described previously as chemotactic for human neutrophils and monocytes. 33 35 Nociceptin secreted by blood leucocytes may trigger the expression of its receptor and influence the release of inflammatory mediators which contribute to the process of inflammation and/or pain. 31 36-38 In addition, a potential relationship between nociceptin and MAPKs has been reported. 31 39 40 Controlling inflammatory diseases via the peripheral nociceptin-NOP system has been suggested as a possible approach in the development of new agents in the treatment of inflammation and pain. 
Conclusions
In PMA induced upregulation of nociceptin expression in MM6, the ERK, JNK, and p38-dependent pathways seem to be utilized. These pathways involved in nociceptin modulation represent new insights in the mechanisms of pain and inflammatory diseases. 
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